1. Home
  2. FOSL vs SCYX Comparison

FOSL vs SCYX Comparison

Compare FOSL & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOSL
  • SCYX
  • Stock Information
  • Founded
  • FOSL 1984
  • SCYX 1999
  • Country
  • FOSL United States
  • SCYX United States
  • Employees
  • FOSL N/A
  • SCYX N/A
  • Industry
  • FOSL Consumer Specialties
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FOSL Consumer Discretionary
  • SCYX Health Care
  • Exchange
  • FOSL Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • FOSL 55.3M
  • SCYX 50.3M
  • IPO Year
  • FOSL 1993
  • SCYX 2014
  • Fundamental
  • Price
  • FOSL $1.15
  • SCYX $1.20
  • Analyst Decision
  • FOSL
  • SCYX Buy
  • Analyst Count
  • FOSL 0
  • SCYX 1
  • Target Price
  • FOSL N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • FOSL 432.2K
  • SCYX 165.3K
  • Earning Date
  • FOSL 11-07-2024
  • SCYX 11-06-2024
  • Dividend Yield
  • FOSL N/A
  • SCYX N/A
  • EPS Growth
  • FOSL N/A
  • SCYX N/A
  • EPS
  • FOSL N/A
  • SCYX N/A
  • Revenue
  • FOSL $1,223,954,000.00
  • SCYX $8,566,000.00
  • Revenue This Year
  • FOSL N/A
  • SCYX N/A
  • Revenue Next Year
  • FOSL N/A
  • SCYX $145.59
  • P/E Ratio
  • FOSL N/A
  • SCYX N/A
  • Revenue Growth
  • FOSL N/A
  • SCYX N/A
  • 52 Week Low
  • FOSL $0.75
  • SCYX $1.15
  • 52 Week High
  • FOSL $1.74
  • SCYX $3.07
  • Technical
  • Relative Strength Index (RSI)
  • FOSL 44.44
  • SCYX 28.95
  • Support Level
  • FOSL $1.02
  • SCYX $1.25
  • Resistance Level
  • FOSL $1.36
  • SCYX $1.37
  • Average True Range (ATR)
  • FOSL 0.12
  • SCYX 0.06
  • MACD
  • FOSL -0.02
  • SCYX -0.01
  • Stochastic Oscillator
  • FOSL 37.23
  • SCYX 9.26

About FOSL Fossil Group Inc.

Fossil Group Inc is a design, innovation and distribution company in consumer fashion accessories. The products include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. The reportable segments are comprised of 1) Americas segment includes sales in Canada, Latin America and the United States. 2) Europe segment includes sales in European countries, the Middle East and Africa. 3) Asia segment includes sales in Australia, China, India, Indonesia, Japan, Malaysia, New Zealand, Singapore, South Korea and Thailand. Each reportable operating segment includes sales to wholesale and distributor customers, and sales through Company-owned retail stores and e-commerce activities based on the location of the selling entity.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: